scholarly journals [68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer

2021 ◽  
Vol 14 (8) ◽  
pp. 713
Author(s):  
Ute Hennrich ◽  
Matthias Eder
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
Positron Emission Tomography ◽  
Pet Imaging ◽  
The United States ◽  
Emission Tomography ◽  
Prostate Specific Membrane Antigen ◽  
Therapy Planning ◽  
Positron Emission ◽  
Specific Membrane

For the positron emission tomography (PET) imaging of prostate cancer, radiotracers targeting the prostate-specific membrane antigen (PSMA) are nowadays used in clinical practice. Almost 10 years after its discovery, [68Ga]Ga-PSMA-11 has been approved in the United States by the Food and Drug Administration (FDA) as the first 68Ga-radiopharmaceutical for the PET imaging of PSMA-positive prostate cancer in 2020. This radiopharmaceutical combines the peptidomimetic Glu-NH-CO-NH-Lys(Ahx)-HBED-CC with the radionuclide 68Ga, enabling specific imaging of tumor cells expressing PSMA. Such a targeting approach may also be used for therapy planning as well as potentially for the evaluation of treatment response.

scholarly journals Current status of radioligand therapy and positron-emission tomography with prostate-specific membrane antigen

2020 ◽  
Vol 34 (12) ◽  
pp. 879-883
Author(s):  
Masayuki Inubushi ◽  
Hiroyuki Miura ◽  
Ichiei Kuji ◽  
Kimiteru Ito ◽  
Ryogo Minamimoto
Keyword(s):  
Prostate Cancer ◽  
Positron Emission Tomography ◽  
The United States ◽  
Emission Tomography ◽  
Current Status ◽  
Prostate Specific Membrane Antigen ◽  
Radioligand Therapy ◽  
Positron Emission ◽  
Psma Pet ◽  
Specific Membrane

AbstractProstate-specific membrane antigen (PSMA) is a transmembrane glycoprotein highly expressed by prostate cancer cells. PSMA-based radioligand therapy (RLT) emerged as a promising therapeutic option for prostate cancer in the early 2000s, and has been clinically validated with great enthusiasm during these past two decades. Last year, the European Association of Nuclear Medicine (EANM) published the procedure guidelines for the safe clinical practice of Lutetium-177 (177Lu)-labelled PSMA RLT. In addition, PSMA RLT with alpha-ray-emitting radioisotopes has been also developed recently. Following the clinical use of 177Lu-PSMA RLT, PSMA-targeted positron-emission tomography (PET) with Gallium-68 (68Ga) has been performed inevitably for “theranostics” for the last decade; prostate cancer is going to be treated with PSMA-RLT based on the diagnosis by PSMA-PET. Furthermore, the diagnostic usefulness of 68Ga-PSMA PET has been documented in various diseases beyond prostate cancer more recently. Regrettably, Japan is behind European countries and the United States in this field, and has just made a belated start of their clinical trials. In this review article, we briefly overviewed the current status of PSMA RLT and PSMA PET. We hope that this topic will be a particular focus of attention for most ANM readers in Japan, and that our efforts will help to facilitate the early approval of PSMA RLT and PSMA PET by the Japanese government even if only slightly.

Sign in / Sign up

Export Citation Format

Share Document